Axelyf is an inflammation- and autoimmunity focused biopharma with exciting assets in preclinical development. These include first-in-class NCE lead programs with blockbuster potential for RA and autoimmune disease, leveraging proprietary lipid delivery technologies. Our AXL technology for RNA delivery is emerging best-in-class with unmatched potency ready for translation to human therapeutic programs. The company is looking to partner our assets to support programs outside our areas of interest, using our experience and capabilities to support advancement of RNA therapeutics of the future.